Ruvonoflast

N/A

Report date: 2025/12/25 15:59:24
NME

Base Information

Drug NameRuvonoflast
Drug Alias NameNT-0796
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNACHT, LRR and PYD domains-containing protein 3 inhibitors
TargetsNACHT, LRR and PYD domains-containing protein 3
Therapy Area/IndicationsSystemic Inflammatory Response SyndromeObesityDiabetes Mellitus, Type 2 +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNodthera
China Registration ClassN/A

Develop Information

Active CompaniesNodThera LtdNodthera
Inactive CompaniesN/A
Active IndicationsSystemic Inflammatory Response SyndromeObesityDiabetes Mellitus, Type 2 +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A